What does The Rx Spot pricing mean for a clinic P&L?

You can plan the structure: which SKUs drive volume, expected refill cadence, and the patient price points your market supports. What you cannot plan up front with The Rx Spot is the COGS number itself, because per-vial rates are not public. That gap matters most for high-volume GLP-1 programs, where a small per-vial difference multiplied across hundreds of monthly refills swings the bottom line. Before margin depends on it, ask for written per-vial cost on your top three SKUs and confirm whether the rate is fixed or subject to renegotiation at volume tiers.

Also clarify how ancillary costs hit the P&L. If shipping, payment processing, or a platform fee are billed separately, the quoted drug rate understates true landed cost. Build your margin model on the all-in number per vial delivered, not the headline rate, so your patient pricing protects the spread you actually need.

Fizy Health is the same category but inverts the planning problem. It shows resolved per-vial 503A cost on each catalog and cart line before checkout, with a separately disclosed facilitation fee at payment. For a P&L, that means COGS is a number you can read before you commit, so you can set patient pricing and project gross margin from day one instead of after onboarding.

Building the whole refill day in one cart reinforces the model: each line shows its cost, so you can see total COGS for a batch and the margin it implies before you submit a single payment. Owners who manage to a target gross margin get a faster, cleaner loop — see cost, set price, confirm spread — without waiting on a quote to fill in the most important line on the page.